Cargando…

Clinical characteristics and outcomes of a patient population with atypical hemolytic uremic syndrome and malignant hypertension: analysis from the Global aHUS registry

INTRODUCTION: Atypical hemolytic uremic syndrome (aHUS) is a rare form of thrombotic microangiopathy (TMA) often caused by alternative complement dysregulation. Patients with aHUS can present with malignant hypertension (MHT), which may also cause TMA. METHODS: This analysis of the Global aHUS Regis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Halimi, Jean-Michel, Al-Dakkak, Imad, Anokhina, Katerina, Ardissino, Gianluigi, Licht, Christoph, Lim, Wai H., Massart, Annick, Schaefer, Franz, Walle, Johan Vande, Rondeau, Eric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090001/ https://www.ncbi.nlm.nih.gov/pubmed/36152218 http://dx.doi.org/10.1007/s40620-022-01465-z

Ejemplares similares

Pregnancy-triggered atypical hemolytic uremic syndrome (aHUS): a Global aHUS Registry analysis
por: Fakhouri, Fadi, et al.
Publicado: (2021)

The global aHUS registry: methodology and initial patient characteristics
por: Licht, Christoph, et al.
Publicado: (2015)

Prognostic utility of ADAMTS13 activity for the atypical hemolytic uremic syndrome (aHUS) and comparison of complement serology between aHUS and thrombotic thrombocytopenic purpura
por: Oh, Jisu, et al.
Publicado: (2019)

Baseline characteristics and evolution of Brazilian patients with atypical hemolytic uremic syndrome: first report of the Brazilian aHUS Registry
por: Vaisbich, Maria Helena, et al.
Publicado: (2022)

Atypical hemolytic uremic syndrome (aHUS) responsive to mycophenolate mofetil: A case report from Nepal
por: Gurung, Jyoti, et al.
Publicado: (2022)

Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case report
por: Ohanian, Maro, et al.
Publicado: (2011)

An innovative and collaborative partnership between patients with rare disease and industry-supported registries: the Global aHUS Registry
por: Woodward, Len, et al.
Publicado: (2016)

Functional Assessment of Fatigue and Other Patient-Reported Outcomes in Patients Enrolled in the Global aHUS Registry
por: Greenbaum, Larry A., et al.
Publicado: (2020)

aHUS caused by complement dysregulation: new therapies on the horizon
por: Waters, Aoife M., et al.
Publicado: (2010)

Complement therapy in atypical haemolytic uraemic syndrome (aHUS)
por: Wong, Edwin K.S., et al.
Publicado: (2013)

Eculizumab Safety: Five-Year Experience From the Global Atypical Hemolytic Uremic Syndrome Registry
por: Rondeau, Eric, et al.
Publicado: (2019)

Erratum to: aHUS caused by complement dysregulation: new therapies on the horizon
por: Waters, Aoife M., et al.
Publicado: (2012)

Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment
por: Walle, Johan Vande, et al.
Publicado: (2016)

Atypical Hemolytic Uremic Syndrome (aHUS) and Adenosine Deaminase (ADA)-Deficient Severe Combined Immunodeficiency (SCID)—Two Diseases That Exacerbate Each Other: Case Report
por: Bogdał, Anna, et al.
Publicado: (2021)

Atypical Hemolytic Uremic Syndrome: Differential Diagnosis from TTP/HUS and Management
por: Yenerel, Mustafa N.
Publicado: (2014)

Exploratory Prognostic Biomarkers of Complement-Mediated Thrombotic Microangiopathy (CM-TMA) in Adults with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of a Phase III Study of Ravulizumab
por: Cammett, Tobin J., et al.
Publicado: (2022)

Clinical Characteristics and Outcome of Canadian Patients Diagnosed With Atypical Hemolytic Uremic Syndrome
por: Lapeyraque, Anne-Laure, et al.
Publicado: (2020)

A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)
por: Rathbone, John, et al.
Publicado: (2013)

Remission of aHUS neurological damage with eculizumab
por: Ávila, Ana, et al.
Publicado: (2015)

Compound Haplotype Variants in CFH and CD46 Genes Determine Clinical Outcome of Atypical Hemolytic Uremic Syndrome (aHUS)—A Series of Cases from a Single Family
por: Furmańczyk-Zawiska, Agnieszka, et al.
Publicado: (2021)

Correction to: Exploratory Prognostic Biomarkers of Complement-Mediated Thrombotic Microangiopathy (CM-TMA) in Adults with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of a Phase III Study of Ravulizumab
por: Cammett, Tobin J, et al.
Publicado: (2023)

Eculizumab and aHUS: Spotlight on Patient-Centered Care
por: Rafat, Cédric, et al.
Publicado: (2020)

Immunosuppressive Therapy of Antibody-Mediated aHUS and TTP
por: Kelen, Kata, et al.
Publicado: (2023)

Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement
por: Pape, Lars, et al.
Publicado: (2016)

Ravulizumab for the Treatment of aHUS in Adults: Improving Quality of Life
por: Legendre, Christophe, et al.
Publicado: (2021)

Familial Atypical Hemolytic Uremic Syndrome: A Review of Its Genetic and Clinical Aspects
por: Bu, Fengxiao, et al.
Publicado: (2012)

Relevance of Bacteriophage 933W in the Development of Hemolytic Uremic Syndrome (HUS)
por: Del Cogliano, Manuel E., et al.
Publicado: (2018)

Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS)
por: Scheiring, Johanna, et al.
Publicado: (2008)

The genetics of atypical hemolytic uremic syndrome
por: Feitz, Wouter J. C., et al.
Publicado: (2018)

Can eculizumab be discontinued in aHUS?: Case report and review of the literature
por: Sahutoglu, Tuncay, et al.
Publicado: (2016)

Eculizumab Treatment for Postpartum HELLP Syndrome and aHUS—Case Report
por: Lokki, A. Inkeri, et al.
Publicado: (2020)

Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient
por: Bouwmeester, Romy N., et al.
Publicado: (2021)

Underlying Genetics of aHUS: Which Connection with Outcome and Treatment Discontinuation?
por: Spasiano, Andrea, et al.
Publicado: (2023)

Treatment of enterohemorrhagic Escherichia coli (EHEC) infection and hemolytic uremic syndrome (HUS)
por: Goldwater, Paul N, et al.
Publicado: (2012)

Eculizumab Use for Kidney Transplantation in Patients With a Diagnosis of Atypical Hemolytic Uremic Syndrome
por: Siedlecki, Andrew M., et al.
Publicado: (2018)

An Atypical Case of Shiga Toxin Producing-Escherichia Coli Hemolytic and Uremic Syndrome (STEC-HUS) in a Lung Transplant Recipient
por: Manière, Louis, et al.
Publicado: (2019)

Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS
por: Valoti, Elisabetta, et al.
Publicado: (2019)

Functional similarity of ABP 959 and eculizumab in simulated serum models of aHUS and NMOSD
por: McBride, Helen J., et al.
Publicado: (2023)

Atypical hemolytic uremic syndrome
por: Loirat, Chantal, et al.
Publicado: (2011)

Atypical Hemolytic Uremic Syndrome
por: Kavanagh, David, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_siitqpi1vh7625efcgcfm6s749